GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. – GRCL

NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Gracell Biotechnologies Inc. (NasdaqGS: GRCL) to AstraZeneca. Under the terms of the proposed transaction, shareholders of Gracell will receive $2.00 per ordinary share in cash at closing (equivalent to $10.00 per ADS of Gracell), plus a non-tradable contingent value right of $0.30 per ordinary share in cash (equivalent to $1.50 per ADS of Gracell) payable upon achievement of a specified regulatory milestone. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.


If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-grcl/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC

Lewis S. Kahn, 855-768-1857

KSF Managing Partner

[email protected]